Trial Profile
A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Telcagepant (Primary) ; Rizatriptan
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Chibret; Merck Sharp & Dohme
- 19 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database
- 04 Jul 2012 Company added in association field as reported by European Clinical Trials Database.
- 04 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.